Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Neurobiol Aging. 2014 Mar 11;35(9):2096–2106. doi: 10.1016/j.neurobiolaging.2014.03.006

Fig. 3.

Fig. 3

Boxplots of the FDG ratio (partial volume corrected [PVCY]) in the AD-signature meta-ROI among 639 elderly (age ≥70) CN participants, stratified by low (SUVr < 1.5) or high (SUVr ≥ 1.5) PiB retention and APOE ε4 carriers and noncarriers. The only pairwise comparisons that reached a nominal level of significance (uncorrected for multiple comparisons) were low PiB/APOE ε4 noncarrier versus high PiB/APOE ε4 carrier (p < 0.001) and high PiB/APOE ε4 noncarrier versus high PiB/APOE ε4 carrier (p = 0.03). There were 365 low PiB/APOE ε4 noncarriers, 74 low PiB/APOE ε4 carriers, 115 high PiB/APOE ε4 noncarriers, and 85 high PiB/APOE ε4 carriers. Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CN, cognitively normal; FDG, 18F-fluorodeoxyglucose; PiB, 11C-Pittsburgh compound B; ROI, region of interest; SUVr, standardized uptake value ratio.

HHS Vulnerability Disclosure